EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CytoSorbents's enterprise value is $51.97 Mil.
CytoSorbents's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.12 Mil. Therefore, CytoSorbents's EV-to-EBITDA for today is -1.78.
The historical rank and industry rank for CytoSorbents's EV-to-EBITDA or its related term are showing as below:
CTSO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.95 Med: -12.54 Max: -1.28
Current: -1.78
During the past 13 years, the highest EV-to-EBITDA of CytoSorbents was -1.28. The lowest was -47.95. And the median was -12.54.
CTSO's EV-to-EBITDA is ranked worse than 100% of 484
companies
in the Medical Devices & Instruments industry
Industry Median: 16.065
vs CTSO: -1.78
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
CytoSorbents EV-to-EBITDA Historical Data
The historical data trend for CytoSorbents's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoSorbents's EV-to-EBITDA
For the Medical Devices subindustry, CytoSorbents's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoSorbents's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CytoSorbents's EV-to-EBITDA falls into.
CytoSorbents EV-to-EBITDA Calculation
CytoSorbents's EV-to-EBITDA for today is calculated as:
CytoSorbents's current Enterprise Value is $51.97 Mil.
CytoSorbents's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents (NAS:CTSO) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CytoSorbents's PE Ratio for today is calculated as:
CytoSorbents's share price for today is $0.88.
CytoSorbents's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.640.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of CytoSorbents's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoSorbents Corp is involves in the treatment of life-threatening conditions in the intensive care (ICU) and cardiac surgery using blood purification via proprietary polymer adsorption technology. It has a number of products commercialized and in development based on this technology platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTSO has been successfully added to your 